BC Week In Review | Dec 21, 2015
Company News

GlaxoSmithKline, Almirall deal

GlaxoSmithKline granted Almirall rights to develop and commercialize Veltin Gel clindamycin/tretinoin worldwide and Altabax retapamulin in the U.S. in exchange for distribution rights to Toctino alitretinoin in Austria, the Czech Republic, Italy, the Netherlands, Poland,...
BC Week In Review | Jun 10, 2013
Clinical News

Ozenoxacin 1%: Phase III data

A double-blind, international Phase III trial in 465 patients aged 2 years and older with bullous or non-bullous impetigo showed that twice-daily topical ozenoxacin 1% cream for 5 days met the primary endpoint of improving...
BioCentury | Nov 19, 2012

Antibiotics reset

There is a consensus among the U.S. government, industry and the medical community that the failure of antibiotic development to keep pace with the evolution of bacterial pathogens constitutes a public health crisis, and that...
BC Week In Review | Jan 23, 2012
Clinical News

Ozenoxacin 1%: Phase III start

Next month, Ferrer will start a double-blind, international Phase III trial to compare twice-daily topical ozenoxacin 1% for 5 days vs. placebo or retapamulin in about 465 patients. Ferrer has exclusive, worldwide rights to ozenoxacin...
BioCentury | Jan 12, 2009

Post-launch report

Post-launch report Sales through 3Q08 of selected drugs approved in 2007 and for which the company discloses sales. Product sales figures as booked by listed companies below. $M; (A) Launch of Mircera delayed in the...
BC Week In Review | Apr 21, 2008
Company News

Medivir, GlaxoSmithKline sales and marketing update

GlaxoSmithKline granted Medivir rights to co-promote dermatology products, selected anti-infective products and Zyban bupropion for smoking cessation in Sweden. The deal includes Betnovat betametason to treat eczema and psoriasis, Relenza zanamivir to treat influenza virus...
BioCentury | Jan 7, 2008

New products to watch

New products to watch Company Product Indication Location Acambis (LSE:ACM) ACAM2000 Prevent smallpox in subjects at high risk of exposure U.S. Actelion (SWX:ATLN) Tracleer bosentan Reduce the number of new digital ulcers in patients with...
BC Week In Review | Jul 30, 2007
Company News

GlaxoSmithKline sales and marketing update

GSK disclosed that in June it launched its Cervarix HPV vaccine to prevent cervical cancer in Australia, Seretide salmeterol/fluticasone propionate to treat chronic obstructive pulmonary disease (COPD) and asthma in Japan, Arixtra fondaparinux to prevent...
BC Week In Review | Jul 30, 2007
Clinical News

Altabax retapamulin regulatory update

The EC approved an MAA for Altargo retapamulin to treat impetigo. GSK markets the pleuromutilin antibiotic in the U.S. as Altabax for the same indication. GlaxoSmithKline plc (LSE:GSK; GSK), London, U.K.   Product: Altabax retapamulin...
BioCentury | Jul 2, 2007

2Q approvals

2Q approvals Company Approval Actelion (SWX:ATLN) EC approves Tracleer bosentan to reduce the number of new digital ulcers in patients with systemic sclerosis and ongoing digital ulcer disease Alexion (ALXN) EC approves Soliris eculizumab to...
Items per page:
1 - 10 of 24